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Abstract
Fibromuscular dysplasia (FMD) is a nonatherosclerotic vascular disease leading to steno-
sis, dissection and aneurysm affecting mainly the renal and cerebrovascular arteries. FMD
is often an underdiagnosed cause of hypertension and stroke, has higher prevalence in
females (~80%) but its pathophysiology is unclear. We analyzed ~26K common variants
(MAF>0.05) generated by exome-chip arrays in 249 FMD patients and 689 controls. We
replicated 13 loci (P<10−4) in 402 cases and 2,537 controls and confirmed an association
between FMD and a variant in the phosphatase and actin regulator 1 gene (PHACTR1).
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Three additional case control cohorts including 512 cases and 669 replicated this result
and overall reached the genomic level of significance (OR = 1.39, P = 7.4×10−10, 1,154
cases and 3,895 controls). The top variant, rs9349379, is intronic to PHACTR1, a risk locus
for coronary artery disease, migraine, and cervical artery dissection. The analyses of geo-
metrical parameters of carotids from ~2,500 healthy volunteers indicate higher intima
media thickness (P = 1.97×10−4) and wall to lumen ratio (P = 0.002) in rs9349379-A carri-
ers, suggesting indices of carotid hypertrophy previously described in carotids of FMD
patients. Immunohistochemistry detected PHACTR1 in endothelium and smooth muscle
cells of FMD and normal human carotids. The expression of PHACTR1 by genotypes in pri-
mary human fibroblasts showed higher expression in rs9349379-A carriers (N = 86, P =
0.003). Phactr1 knockdown in zebrafish resulted in dilated vessels indicating subtle
impaired vascular development.
We report the first susceptibility locus for FMD and provide evidence for a complex
genetic pattern of inheritance and indices of shared pathophysiology between FMD and
other cardiovascular and neurovascular diseases.
Author Summary
Fibromuscular Dysplasia (FMD) is a vascular disease characterized by a succession of
occlusions and dilatation of medium-sized arteries (e.g renal, carotid or coronary arteries)
with important health consequences,mainly resistant hypertension and stroke. FMD is an
atypical vascular disease because it is not associated with overweight or dyslipidemia and
80% of patients are early middle aged women. Our genetic study conducted in>1100
patients and>3800 controls demonstrate that a common variant rs9349379 located on
chromosome 6 in the phosphatase and actin regulator 1 gene (PHACTR1) increases by
~40% the risk of FMD. This is the first time a genetic risk factor is reported for FMD
because it has been longtime considered rare and potentially under a Mendelian mode of
inheritance.We also show that rs9349379 correlates with the expression of PHACTR1 in
fibroblasts from FMD patients and controls. Interestingly, the same allele that increases
the risk of FMD is at risk for cervical artery dissection and migraine, often reported in
FMD patients but protective frommyocardial infarction and coronary disease, where ath-
erosclerosis is more common. The clear role of PHACTR1 in maintaining vascular well
integrity is not fully elucidated. Using a specific antibody we detected PHACTR1 both on
endothelial and smooth muscle cells of human FMD and control carotids, which suggests
that PHACTR1 may have multiple functions depending on the cell type and the degree of
atherosclerosis of the arteries.
Introduction
Fibromuscular dysplasia (FMD) is a non-atherosclerotic and non-inflammatory vascular dis-
ease leading to stenosis, aneurysm, dissection, and/or occlusion of medium-sized arteries, in
particular the renal and extracranial cerebrovascular arteries [1–3]. FMD predisposes to hyper-
tension, transient ischemic attack and stroke [2,3]. Intriguingly, 75% to 90% of FMD patients
are women[3,4] and FMD is increasingly considered to be a silent and under-diagnosed condi-
tion [5].
Genetic Investigation of FMD
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The angiography-based classification of renal FMD distinguishes between patients with
multifocal stenoses, including the "string-of-beads” FMD pattern, and unifocal (or focal) FMD
with corresponding differences in sex ratio, median age of diagnosis and smoking status [6,7].
The pathogenesis of FMD is unknown and there are strong arguments in favor of a genetic
origin.We have previously reported familiality of FMD in ~10% of patients [8]. The US FMD
registry has also described a family history in first or second-degree relatives for FMD (7%)
and aneurysm (23%) [3]. Nonetheless, the unknown status of most of family members com-
promised heritability estimates and made the assessment of the genetic mode of inheritance
difficult. Recently, we investigated the coding genomes from 16 affected siblings and excluded
the existence of a major mutated gene in familial FMD [9]. The complexity of the diagnosis
based on computed tomography angiography (CTA) and/or magnetic resonance angiography
(MRA) and a general lack of awareness among affected patients and clinicians result in an
under-diagnosis bias.
To advance our understanding of the etiology of FMD, we performed a genetic association
study that identifies a first genetic susceptibility locus for FMD. In addition to the high preva-
lence of asymptomatic FMD (~3–6%) [3,10] and the existence of environmental modifiers (e.g
female hormones, lifetimemechanical stress) our study provides genetic and functional evi-
dence supporting for the first time a complex genetic basis for FMD.
Results
Association of rs9349379 in PHACTR1 with FMD
We carried-out a multi-stage genetic association study, including a discovery and four valida-
tion case control cohorts, to identify genetic determinants of FMD. All FMD patients and con-
trols were of European ancestry and have similar overall clinical features (Table 1). First, we
analyzed 25,606 common (minor allele frequency 0.05) genetic variants in 249 FMD cases
and 689 controls. Despite the small sample size, we also performed stratified analyses including
only females (193 patients and 416 controls). Associations across chromosomes are summa-
rized in Manhattan Plots (S2 Fig). In the global analysis, no SNP achieved the adjusted signifi-
cance threshold for multiple testing (P = 1.95×10−6, S2 Fig). Nevertheless, the strongest
association signal located on chromosome 6 (rs9349379, effect allele frequency (EAF) in
Table 1. Clinical features of the study populations.
Cohorts N Females (%) Age at exam (yrs) Multifocals (%) HTN (%) HTN diagnosis (yrs) Study Design
RVDRC Cases 249 193 (78%) 44.12 ± 14.31 164 (66%) 228 (92%) 36.6 ± 13.65 Clinical recruitment
SU.VI.MAX controls 689 416 (60%) 49.80 ± 6.20 NR NA NA Population based
ARCADIA cases 402 319 (79%) 42.46 ± 15.68 273 (68%) 341 (85%) 34.9 ± 15.15 Clinical recruitment
PPS3 controls 2,537 1012 (40%) 58.73 ± 5.94 NR 0 NR Population based
Mayo Cases 143 119 (83)% 61.48 ± 13.43 NA 108 (76%) 58.75 ± 10.31 Clinical recruitment
Mayo Controls 333 286 (86%) 65.78 ± 10.50 NR 169 (51%) 62.52 ± 10.25 Clinical recruitment
UM/Cleveland Cases 304 295 (97%) 53.93 ± 10.45 254 (84%) 193 (63%) NA Clinical recruitment
UM/Cleveland Controls 289 280 (97%) 55.13 ± 9.97 NR NA NA Clinical recruitment
DEFINE-FMD Cases 65 65 (100%) 57.03 ± 10.13 65 (100%) 41 (63%) 42.68 ± 13.05 Clinical recruitment
DEFINE-FMD Controls 47 47 (100%) 50.70 ± 9.38 NR 4 (9%) 55.25 ± 13.05 Clinical recruitment
HTN, Hypertension
NR, Not Relevant
NA, Not Available.
doi:10.1371/journal.pgen.1006367.t001
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cases = 0.70, odds ratio (OR) = 1.65, P = 1.47×10−5) surpasses the adjusted threshold in the
female only analysis (OR = 1.99, P = 8.16 × 10−7, S2 Fig, S1 Table).
In addition to rs9349379, we selected for follow-up loci that showed suggestive association
with FMD (P<10−3) and were located in or near either biological candidate genes (e.g extracel-
lular matrix degradation) or previous cardiovascular genome-wide association (GWAS) sig-
nals. We also prioritized four SNPs located within one megabase interval around rs9349379,
the top associated variant. The first follow-up study included 402 FMD patients from the
ARCADIA registry, who had similar clinical characteristics to the patients of the discovery
stage and were compared to 2,537 controls from PPS3 (Table 1). Of the 16 SNPs selected, 13
passed genotyping QC criteria in cases and controls. Three SNPs, all located in the PHACTR1
locus, showed replicated association with FMD (rs9349379-A, P = 7.21 × 10−4, rs9369640-C,
P = 8.45 × 10−4 and rs1332844-C, P = 1.72 × 10−3, S1 Table). Conditioned regression analyses
for rs9349379 in the case control cohort including the discovery and first follow-up study sam-
ples indicated association signal redundancy for rs9369640 (P = 0.21) and rs1332844 (P = 0.24)
with rs9349379 being the most statistically significant. Next, we investigated the association of
rs9349379 with FMD in three additional and independent case-control cohorts from the USA.
Overall, of the four follow-up studies, three showed a significant effect of rs9349379 on the risk
of FMD; all studies showed consistent direction of effect of the FMD risk allele rs9349379-A
beingmore prevalent in FMD cases (Table 2). The associationmeta-analysis included 1,154
FMD patients and 3,895 controls and indicated an overall OR of 1.39 for rs9349379
(EAF = 0.69 in global cases sample), with a high level of significance (P = 7.36×10−10) that is
below the genomic threshold and no indices for heterogeneity between studies (P = 0.574,
Table 2).
As for rare variants (MAF< 5%), we observed62,767 polymorphic variants in the discovery
case control analyses that we analyzed using the SKAT-O gene-based association test. None of
the 9,967 genes covered with at least 2 polymorphic variants showed significant association
Table 2. Association of rs9349379 in PHACTR1 with FMD in five independent case-control cohorts.
Additive model Recessive model
Study Cohorts n AA AG GG EAF (A) OR (95% CI)a P Valuea OR (95% CI)a P Valuea
Discovery RVDRC Cases 249 124 103 22 0.70 1.65 (1.32–2.07) 1.47 × 10−5 1.87 (1.39–2.52) 3.39 × 10−5
SU.VI.MAX controls 689 237 341 111 0.59
Follow-up ARCADIA 393 183 170 40 0.68 1.32 (1.12–1.54) 7.21 × 10−4 1.38 (1.11–1.71) 0.003
PPS3 controls 2537 982 1174 381 0.62
Mayo Cases 143 62 65 16 0.66 1.37 (1.02–1.83) 0.034 1.94 (0.91–4.16) 0.09
Mayo Controls 333 116 159 58 0.59
UM/Cleveland Cases 304 145 130 29 0.69 1.31 (1.03–166) 0.026 1.43 (0.96–2.14) 0.08
UM/Cleveland Controls 289 116 135 38 0.63
DEFINE-FMD Cases 65 41 18 6 0.77 1.39 (0.77–2.49) 0.276 1.38 (0.99–1.91) 0.05
DEFINE-FMD Controls 47 22 22 3 0.70
Meta-analysisb All Cases 1154 555 486 113 0.69 1.39 (1.25–1.54) 7.36 × 10−10 1.50 (1.3–1.73) 1.39 × 10−8
All Controls 3895 1473 1831 591 0.61
OR, Odds Ratio
CI, Confidence Interval
EAF, Effect Allele Frequency.
aOdds Ratio (OR) and P values were computed by logistic regression under the additive and recessive genetic model.
bMeta-analysis was performed using inverse variance-weighted method. Heterogeneity between cohorts was tested using Cochran’s Q statistics and was
not significant (Padd = 0.574;Prec = 0.483).
doi:10.1371/journal.pgen.1006367.t002
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with FMD after Bonferroni correction (P = 5.02 × 10−6, strongest gene P = 1.42 × 10−4), or bio-
logical candidacy among best scoring genes, which discourages follow-up genotyping or
sequencing efforts in larger samples.
Association of rs9349379 with carotid parameters in PPS3
Here we aimed to characterize the association of rs9349379 with artery thickness and stiffness
using a non-invasive method in 2,458 healthy volunteers. Genetic association analyses indicate
significant association between the FMD increasing risk allele rs9349379-A and greater intima-
media thickness (IMT) (βadd = 11.65 μm, Padd = 1.65×10−4, Fig 1) and wall to lumen ratio
(WLR) (βadd = 0.004, Padd = 0.002, Fig 1), and decreased circumferential wall stress at DBP
(βadd = -0.72, Padd = 0.004, S2 Table). Interestingly, despite their smaller number (N = 975)
compared to males (N = 1,483), females present more accentuated effect of the rs9349379-A
allele on IMT (βadd = 14.83 μm, Padd = 0.001) andWLR (βadd = 0.006, Padd = 0.003). However,
we detected no significant interaction with sex. rs9349379-A also associated with increased
wall cross-sectional area (βadd = 0.24 mm2, Padd = 8.67×10−4, S2 Table), peripheral SBP (βadd =
0.70 mmHg, Padd = 0.009, S2 Table) and central pulse pressure (βadd = 0.62 mmHg, Padd =
0.002, Fig 1).
PHACTR1 expression studies
Variant rs9349379 resides in the fourth intron of the phosphatase actin regulator 1 gene
(PHACTR1) in a putative regulatory sequence.We assessed PHACTR1 expression using quan-
titative real time PCR in mRNAs from primary cultured human fibroblasts. PHACTR1 expres-
sion did not differ in fibroblasts from FMD patients compared to age and sex matched controls
(Fig 2). However, stratifying by rs9349379 genotype indicated increased expression in individ-
uals carrying the FMD risk allele rs9349379-A (Padd = 0.003, Fig 2). At the protein level, using
a specific antibody, we found that PHACTR1 is expressed in endothelial and medial smooth
muscle cells of carotid arteries from both normal and FMD patients (Fig 2).
Functional role of Phactr1 in vascular development
Given the unclear role for PHACTR1 in vascular development and maintenance, we assessed
the effect of PHACTR1 perturbation in the zebrafish. Morpholino injected embryos had unde-
tectable phactr1 transcript levels at 72 hours post fertilizationwhile overall morphologywas
unchanged (S3 Fig). Compared to control injected zebrafish, phactr1 knockdown resulted in a
marked disorganization of the developing hepatic portal vein and the segmental vessels in the
developing trunk (Fig 3 and S3 Fig). Further analysis of the diameter of three major peripheral
vessels, the dorsal aorta, caudal artery and posterior cardinal vein, demonstrated a nearly 8%
dilatation (P<0.05) of the posterior cardinal vein in phactr1 suppressed embryos.
Discussion
Our study describes for the first time the genetic association of rs9349379, a common variant
in PHACTR1, with arterial fibromuscular dysplasia (FMD).We demonstrate that this common
variant increases by ~40% the risk of FMD in five independent case-control studies. These
findings are based on genetic data from 1,154 FMD patients and 3,895 controls, the largest
investigation conducted so far to elucidate the genetic basis of this intriguing vascular disease
with unknown etiological origin and challenging clinical features.
To date, the genetic investigation on FMDwas limited to the screening of candidate genes
involved in rare vascular and arterial syndromes, and/or the study of underpowered series of
Genetic Investigation of FMD
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patients.[9,11,12] For long considered a rare disease, FMD has also been hypothesized to be
under the genetic control of highly penetrant genetic defects. Our study provides the first evi-
dence for a complex genetic pattern of inheritance for FMD, involving a common genetic allele
(frequency = 0.60 in the general population). The identification of a genetic susceptibility locus
for FMD supports the concept that this disease is controlled by a large number of genetic
Fig 1. Association between rs9349379 and artery thickness in healthy controls. Intima-media
thickness and wall to lumen ratio are presented by genotype in all (A,D) women (B,E) and men (C,F)
participants. We indicated p-values for the linear regression analyses under the additive model adjusted for
age, sex and body surface area.
doi:10.1371/journal.pgen.1006367.g001
Genetic Investigation of FMD
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determinants in strong interaction with various environmental factors, including female sex
and mechanical stresses.
We provide genetic evidence for increased IMT, narrowed artery lumen and no change in
arterial stiffness, even after adjusting for blood pressure, in healthy volunteers carrying the
rs9349379-A, the FMD risk allele. These genetic associations support the observation of carotid
concentric hypertrophy in FMD risk carriers, especially females. This finding is consistent with
previous arterial features reported in FMD patients when compared to age, sex and SBP
matched controls.[13] Circumferential wall stress was decreased in rs9349379-A carriers,
showing that hypertrophy may overcome the moderate increase in blood pressure. Of note, the
effect size of the FMD risk allele on IMT corresponds to approximately five years of aging for
the IMT, when reported to sex and age reference values for arterial geometry,[14] suggesting
potentially an accelerated arterial aging in carriers of the rs9349379-A FMD risk allele.
PHACTR1 was previously identified by several genome-wide association studies (GWAS) as
a risk locus for cardiovascular and neurovascular diseases.PHACTR1 is a confirmed suscepti-
bility locus for coronary artery disease (CAD) and myocardial infarction (MI),[15,16] migraine
[17,18] and more recently cervical artery dissection (CeAD), a rare condition defined as a
mural hematoma in a carotid or vertebral artery and a cause of stroke.[19] Of note, the associa-
tion of rs9349379 is in the opposite direction for FMD, CeAD and migraine, with rs9349379-A
at risk, when compared to CAD and MI with rs9349379[G] allele at risk. Migraine and CeAD
Fig 2. PHACTR1 mRNA expression and immunostaining. (A) PHACTR1 mRNA expression in human fibroblasts.
PHACTR1 mRNA levels were determined by RT-qPCR in cultured fibroblasts from controls (N = 39) and FMD cases (N = 51).
GAPDH expression was used as control for normalization and data are expressed as mean fold change of PHACTR1 relative to
GAPDH. There is a non-significant trend toward overexpression of PHACTR1 in FMD cases compared to controls (P = 0.61,
Mann-Whitney test) whereas significant differences are uncovered after stratification by genotypes (P = 0.003, Kruskal-Wallis
test). (B) Immunostaining of normal and FMD internal carotid using anti-PHACTR1 antibody. PHACTR1 was detected in
endothelium and smooth muscle cells in the media. Staining is mostly cytoplasmic with regular alignment in normal carotids and
typical disorganized cellular structure in media of FMD carotid.
doi:10.1371/journal.pgen.1006367.g002
Genetic Investigation of FMD
PLOS Genetics | DOI:10.1371/journal.pgen.1006367 October 28, 2016 7 / 17
share several clinical features with FMD. Migraine is also more prevalent in females than in
males and it is reported by a third of FMD patients.[3] CeAD is an important risk factor for
subarachnoid hemorrhage stroke, as is cerebrovascular FMD.[3] The investigation of a large
series of CeAD patients indicated that cervical FMD is reported in 5.6% of the patients[20] and
carotid dissection is the presenting manifestation in 12.1% of patients of the US FMD registry.
[3] In contrast to migraine and CeAD, the implication of the same common variant in
PHACTR1 in CAD/MI and FMD is rather unexpected, though it involved a different allele at
the same genetic variant. The clinical link between FMD and CAD/MI is less obvious, except
for the high proportion of FMD in rare forms of MI involving spontaneous coronary artery dis-
section, that also present in young females without atherosclerotic risk factors.[21–23] By
Fig 3. phactr1 modulation in zebrafish affects vascular dimensions and patterning. Two-dimensional projections
obtained from z-series confocal images in the trunk of control and phactr1 knockdown (KD) zebrafish embryos (two
representative images per condition). Green represents the vascular endothelium as marked by EGFP. Greyscale
represents the corresponding DIC bright field image of the fish trunk. DA: Dorsal aorta, SV: Segmental vessel, PCV:
Posterior cardinal vein. Quantification of inner vascular diameter for the dorsal aorta (DA), posterior cardinal vein (PCV) and
caudal artery (CA). (*) represents P<0.05.
doi:10.1371/journal.pgen.1006367.g003
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definition FMD does not involve atherosclerotic stenosis that is concomitant with CAD andMI
through pathogenesis processes (e.g dyslipidemia and inflammation). Future comprehensive
genetic investigation by full GWAS for FMDwill allow the assessment of the putative consistency
and opposition of effects between risk loci for these cardiovascular and neurovascular diseases.
The rs9349379 is intronic to PHACTR1 in a putative noncoding regulatory sequence.
PHACTR1 encodes a phosphatase and actin regulator protein and its function is not fully eluci-
dated. Here we describe significant correlation between rs9349379 genotypes and PHACTR1
expression in human fibroblasts from FMD patients and controls. This association is consistent
with the expression quantitative trait loci (eQTL) data from several artery beds of the Geno-
type-Tissue Expression (GTEx) project and a recent study where increased expression is
reported in human coronary arteries from donors carrying the rs9349379-A.[16] Using a
genome-editing technique with CRISPR-Cas9 applied to human umbilical vein endothelial
cells, the deletion of the sequence containing rs9349379 caused a 35% decrease in PHACTR1
expression and impaired the fixation of the myocyte enhancer factor-2 (MEF2), supporting a
functional regulatory effect of this genetic variant in vitro.[16] However, other transcription
factors may also bind to this site, as the knockdown of the expression of two members of the
MEF2 family did not change PHACTR1 expression.[24]We note that ENCODE ChIP-Seq
data derived from genomes extracted from two immortalized cell lines after stimulation by
estradiol indicates several consistent peaks for ESR1 suggesting a putative regulation of
PHACTR1 by this female hormone. This putative regulation that needs to be established exper-
imentally is consistent with the high proportion (~75–90%) of women among FMD patients.
Molecular studies have also linked PHACTR1 to cell adhesion and migration in angiogene-
sis via vascular endothelial growth factor (VEGF) stimulation.[25,26] In contrast to other stud-
ies,[26,27] Beaudoin et al reported a lack of evidence for the induction of PHACTR1
expression in endothelial cells with pro-angiogenic (VEGF), pro-inflammatory stimulations or
shear stress.[16] Our immunohistochemistry staining of PHACTR1 indicates the presence of
PHACTR1 both in endothelial and smoothmuscle cells of normal and FMD carotid arteries.
The genetic implication of PHACTR1 in FMD, the subtle impairment in the development of
vasculature in zebrafish, in addition to the evidence from recent GWAS describing an increas-
ing number of loci with genes involved in vessel wall biology in CAD and MI[28] all support
PHACTR1 plays a key etiological role in vascular structure. Recent work on PHACTR1 regula-
tion in atherosclerosis showed strong expression in human atherosclerotic plaque macrophages
lipid-laden foam cells, adventitial lymphocytes and endothelial cells.[29] This group also
describes the absence of PHACTR1 in SMCs of healthy and athesclerotic aortas, which is not
supported by our immunostaining on medium-sized arteries using a different anti-body,
though they have detected the expression of an intermediate transcript in SMCs. Further inves-
tigation is required to understand this discrepancy that might reflect PHACTR1 is much more
abundantly expressed in macrophages from atherosclerotic plaques, where this population of
cells is highly represented and biologically active, which is different from the FMD and healthy
vessels without atherosclerosis. Thus, according to rs9349379 genotype, the manifestation of
one specific vascular disease depends on multiple and particular environmental triggers (e.g.
female specific hormonal context, mechanical movements of medium size arteries in the case
of FMD) that are still to be specifically determined for each of these cardiovascular and neuro-
vascular diseases.
In summary, our study provides genetic and functional evidence to support PHACTR1 as a
first susceptibility locus for FMD. Further functional exploration of this locus and more compre-
hensive genetic investigation through genome-wide associationwill provide additional predis-
posing loci to FMD and help understanding the etiologicalmechanisms of non-atherosclerotic
arterial stenosis.
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Methods
Ethics Statement
We obtained individual written informed consent from all participants included in France and
the USA case control studies.
French FMD patients (RVDRC and ARCADIA) from the European Hospital Georges Pom-
pidou (HEGP) are part of the ARCADIA/PROFILE protocol that was approved by the Ile-De-
France research ethics committee (Comité de Protection des Personnes: CPP d’île de France)
on 03/04/2009 (ID: 2009-A00288-49). The ethics committee of the Paris-Cochin hospital
approved the protocols of the SU.VI.MAX study (CCPPRBNo. 706) and PPS3 (CPP No.
2007-A01386-47). PPS3 is declared at ClinicalTrials.gov (Identifier: NCT00741728). Mayo
Clinic case control study is part of the Vascular Diseases Biorepository study and was approved
by the Mayo I Mayo Clinic Institutional ReviewBoards (IRB # 08–008355). UM/Cleveland
case control study was approved by each institution IRB protocols: the University of Michigan
IRB number HUM00044507 and the Cleveland Clinic IRB number 10–318. The DEFI-
NE-FMD study was approved by the Human Research Ethics Committee of the Icahn School
of Medicine at Mount Sinai (Study ID: HS#13-00575/GCO#13–1118 and is registered with
ClinicalTrials.gov Identifier: NCT01967511.
Patients and control populations
We used a three-stage association design. First, we performed an exome-chip based genetic
association in 249 French FMD patients (RVDRC cohort) and 689 controls from SU.VI.MAX
[30]. Second, we followed-up 13 loci in an independent set of 402 French patients (ARCADIA
registry) and 2,537 controls from PPS3 [31]. Three additional studies from the USA totaling
512 patients and 669 controls were used for further replication: Mayo Clinic cohort [32], Uni-
versity of Michigan (UM)/Cleveland Clinic cohort and the DEFINE-FMD study. All partici-
pants are of European ancestry and presented similar clinical characteristics (Table 1) and
homogeneous diagnosis, exclusion and inclusion criteria.
RVDRC and ARCADIA cases. We analyzed unrelated FMD followed-up at the Rare Vas-
cular Diseases Reference Center (RVDRC) of the European Hospital Georges Pompidou
(HEGP), Paris, France. We ascertained patients from the ARCADIA (Assessment of Renal and
CervicalArteryDysplasIA) register, an ongoing national FMD registry at the HEGP, Paris.
The diagnosis of FMD in RVDRC and ARCADIA patients was established using clinical infor-
mation from the medical history, the interpretation of angiography and/or computed tomogra-
phy scan of arterial beds after the exclusion of other causes of arterial stenosis such as
atherosclerosis, Takayasu disease and Elhers Danlos syndrome and neurofibromatosis type 1.
Given the complexity of the interpretation of imaging of vascular diseases, a local panel of
experts including clinicians from the departments of hypertension, radiology, vascularmedi-
cine and medical genetics validated the diagnosis of FMD.
SU.VI.MAX and PPS3 controls. Controls in discovery stage are French Europeans from
the SU.VI.MAX study as previously described [30]. PPS3 controls were 2,537 participants
ascertained from the Paris Prospective Study 3 (PPS3), an ongoing observational French pro-
spective study evaluating the possible implication of numerous vascular health parameters in
cardiovascular disease in healthy subjects aged from 50 to 75 years undergoing a standard
health examination in a large preventive medical center that is subsidized by the French
national insurance system for salaried workers [31].
Mayo Case-Control study. Potential FMD cases were identified from the Mayo vascular
disease bio-repository. Electronic health records of 501 patients were manually reviewed by
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clinicians and the diagnosis was confirmed for 191 patients according to criteria in [1], of
whom 159 had DNA available and 143 (83% females) had high-density genotyping data.
Patients were matched for sex and age (+/- 2 years) to 333 controls without known FMD or
other atherosclerotic vascular diseases.
UM/ClevelandClinic case control study. Patients were recruited at the University of
Michigan (UM) and/or the Cleveland Clinic. UM FMD cases were recruited into an IRB-
approved study through a referral clinic at the University of Michigan and through self-referral
to the study. The Cleveland Clinic cases were enrolled among consecutive patients seen at a dedi-
cated FMD referral clinic. Clinical diagnosis of FMDwas ascertainedby a vascularmedicine spe-
cialist after review of diagnostic imaging and prior to blood sample collection.DNAs from
healthy controls without vascular diseasewere obtained from the Cleveland Clinic GeneBank,
which was approved by the Cleveland Clinic IRB. GenomicDNA was isolated from a peripheral
blood sample and analyzed as described[33].
The DEFINE-FMD Study. Eligible cases were females with an imaging-confirmeddiag-
nosis of multifocal FMD and who fulfilledother accepted diagnostic criteria [1]. Healthy con-
trols were matched to FMD cases according to age and sex, required to be receiving 2 blood
pressure medications, have a bodymass index< 35kg/m2 and to be non-smokers. Healthy
controls underwent physical exam and those with bruits; unexplained hypertension or other
cardiovascular findings were excluded. Exclusion criteria for all subjects includedmale gender,
unifocal FMD, use of immunosuppressive agents, major comorbidities, diseases that may con-
found genetic/genomic analyses (i.e. Crohn’s disease,multiple sclerosis etc.) or any other form
of heritable vascular disease (i.e. Ehlers-Danlos,Marfan, Loeys-Dietz).
Genotyping
Genotypes were generated using the Illumina-HumanExome-12v1 array in RVDRC, SU.VI.
MAX and PPS3,[34] Illumina-Human-Omni-Express-Exome in the DEFINE-FMD Study par-
ticipants, Illumina-Infinium-Human-CoreExome in Mayo Clinic cohorts and by individual
genotyping in ARCADIA (KASP technology) and UM/Cleveland Clinic cohorts (Taqman).
We applied quality control (QC) filters to the discovery cases and controls as recommended
[35] (individual’s call rate< 97%, extreme heterozygosity, sex-discordant, duplicate or related-
ness unsing PLINK (version 1.07).[36] Individuals with non-European ancestry were detected
and excluded (54 cases and 9 controls) using the EIGENSTRAT program[37] and visualized by
principal components analysis (PCA) including HapMap phase 3 samples. Cases and controls
displayed a comparable distribution after ancestry QC (S1 Fig). From 240,748 successfully gen-
otyped SNPs, we excludedmonomorphic variants (n = 129,890), call rate< 99%, deviation
fromHardy-Weinberg Equilibrium in cases and/or controls (P< 10−5) and minor allele fre-
quency (MAF)<0.05 in controls. The final analysis included 25,606 variants (25,138 autosomal
and 468 X-linked) in a sample of 249 FMD cases and 689 controls. Comparable individuals
and markers QCwas applied to follow-up cohorts using arrays (PPS3, Mayo Clinic case control
cohorts, the DEFINE-FMD study) or individual genotyping (ARCADIA and UM/Cleveland
cases control cohort).
Carotid geometry and stiffness measurements in PPS3 cohort
Carotid parameters were measured and calculated as previously reported [34]. Briefly, a 10
MHz 128 transducer linear array probe was positioned on the carotid area. Measurements
were performed on a 4 cm segment of the right common carotid artery, 1 cm proximal to the
bifurcation/sinus throughout the cardiac cycle for 6 seconds. A longitudinal section showing
clear interfaces for blood/intima and media/adventitia was obtained. The system allows real-
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time radiofrequency signal analysis with operator-independent determination of external
diameter (Dext), internal diameter (Dint), and intima-media thickness (IMT) on 128 lines
throughout the cardiac cycle. Distension was measured on 14 lines at high-pulsed radiofre-
quency (600 Hz). The axial resolution was 34 μm for diameter, 17 μm for IMT, and 1.7 μm for
distension.[38] Aortic blood pressure was estimated from the distension waveform according
to van Bortel et al.[39] The distensibility coefficient, representing the elastic properties of the
artery as a hollow structure, was calculated as dLCSA/(LCSA×central PP), where LCSA is the
lumen cross-sectional area and central PP is the aortic pulse pressure. Carotid stiffness (Cstif)
was calculated as DC−0.5 and circumferential wall stress as diastolic blood pressure×Dint/
2×IMT. WCSA is wall cross-sectional area. Young's elastic modulus is calculated as DC−1x3(1
+LCSA/WCSA). Here we examined the association of one genetic variant (rs9349379) with 14
interdependent traits in a sub-sample of 2458 participants (975 females and 1483 males).
Hypertensive participants (BP over 140 and/or 90 mmHg, and/or use of antihypertensive treat-
ments) were excluded to avoid confounding with genetic effects.
Statistical analyses
We tested the association with FMD using logistic regression under the additive genetic model
as implemented in PLINK[36] (version 1.07) in discovery and follow-up studies. In the discov-
ery analysis, we included the first five principal components axes as co-variates to control for
hidden population stratification. The Bonferroni adjusted threshold for significancewas set to
P = 1.95×10−6 to account for multiple testing of 25,606 common variants. We used the inverse
variance-weightedmethod for meta-analysis implemented in Metal [40]. Gene-based analyses
of rare variants was performedusing SKAT-O method as described in.[41] Heterogeneity was
assessedwith Cochran'sQ statistics.We tested the association of rs9349379 with carotid parame-
ters in 2,458 normotensive subjects (975 females and 1483 males) from PPS3 using a linear
regression on an additive geneticmodel including age, sex, body surface area (BSA), and mean
bloodpressure (MBP) as covariates when relevant. Before performing the analyses, all parameters
(all quantitative traits) were quantile-transformed to a standard normal distribution. The 14 traits
fall into threemain carotid parameters categories: geometry (intima-media-thickness, external
and internal carotid diameters, wall to lumen ratio and circumferential wall stress), arterial stiff-
ness (stiffness, cross-sectional distensibility, Young’s elastic modulus, cross-sectional compliance,
and wall cross-sectional area) and central blood pressure (systolic, diastolic and aortic bloodpres-
sure). Considering that carotid parameters are interdependent, we applied a Bonferroni correc-
tion (Padj = 0.017) for the threemain categories as recommended [34].
PHACTR1 expression in fibroblasts
We analyzed the expression of PHACTR1 from fibroblasts of skin biopsy samples of 104 indi-
viduals (51 FMD, 39 controls, 12 undetermined).Genotypes and detectable expression levels
were available in 86 individuals.
Fibroblasts of the DEFINE-FMDStudy were derived from skin biopsy samples using stan-
dard explant techniques from 103 individuals (46 FMD and 57 controls). Briefly, skin biopsy
samples were dissected into small pieces and cultured under cover slips in DMEM/F12 media
containing 20% fetal bovine serum, 1% antibiotic-antimycotic solution, 1% 200 mM L-gluta-
mine, 1% 100mM Sodiumpyruvate, and 1%MEMNon-Essential Amino Acids (all from Life
Technologies, Grand Island, NY, USA) at 37°C in 5% CO2. Cell culture mediumwas replaced
every 48 hours and confluent cells from passages 2–3 were used for RNA extractions. RNA was
then converted to cDNA using iscript cDNA synthesis kit (Bio Rad, Hercules, CA, USA) and
quantitative real time PCR (qRT-PCR) was performedusing SYBR green fastmix low rox
Genetic Investigation of FMD
PLOS Genetics | DOI:10.1371/journal.pgen.1006367 October 28, 2016 12 / 17
(Quanta Biosciences,Gaithersburg,MD, USA). Fibroblasts from the University of Michigan were
obtained through the Coriell Biorespository (Camden, NJ, USA) for 20 subjects with FMD and
apparently 20 healthy control subjects and matched for passage number. DNAs and genotypes
were not available. Confluent cells from passages 6–8 were used to extract RNA and generate
cDNAs to assess PHACTR1 expression according to culture and extraction protocol described for
the DEFINE-FMD study. Fibroblasts from the Department of genetic, HGEP study were derived
from skin biopsy samples from patients followed up for unknown arterial diseases where FMD
and Elhers Danlos syndrome were discarded. FMD status is not available. SNP rs9349379 was
genotyped by direct forward and reverse sequencing (BigDye Terminator kit v3.1 cycle sequenc-
ing kit) and run on an ABI Prism 3730XLDNA Analyzer Sequencer (Perkin Elmer Applied Bio-
systems, Foster City, CA). Cell culture and RNA extraction conditions and reagent were identical
to the DEFINE-FMD study. Informed consent was obtained from all patients of all centers.
In total, we analyzed the expression of PHACTR1 from fibroblasts of skin biopsy samples of
104 individuals (51 FMD, 39 controls, 12 undetermined), and 86 individuals had genotypes
and relevant expression levels. The expression of PHACTR1 transcript variant 1 (NCBI Refer-
ence Sequence:NM_030948.2) and GAPDH, which was used as normalization control, was
determined by RT-qPCR following the MIQE guidelines.[42]All expression studies from the
three laboratories used the same following primers: PHACTR1 fwd ATGACCGCAGGGCAG
ATAAG, rev TTCGGATGGCAGCTTTGTCT; GAPDH fwd GGGTGTGAACCATGAGAAG
TATGA, rev GGTGCAGGAGGCATTGCT. The efficacy and efficiencyof amplifications for
PHACTR1 and GAPDH were equivalent as determined by the linearity tests: (PHACTR1 effi-
cacy 1.97 and efficiency98.7%); (GAPDH efficacy 2.04 and efficiency102%). The specificity of
amplification products was verified by the presence of a single peak in the melting temperature
curve analysis. Outliers displaying GAPDH Cq values different from the mean or a ΔCq value
>14 (Cq value PHACTR1 –Cq value GAPDH) were filtered out. Good correlations for RT and
technical qPCR replicates were obtained. Given that data obtained from three independent lab-
oratories was equivalent: mean Cq for GAPDH 17,41 +/- 0,65 and mean Cq for PHACTR1 was
30.46 +/- 1.19, we pooled them as indicated to gain power, especially for the correlation by
genotypes where few samples per study were GG carriers. Data is presented as the mean fold
change in the expression of PHACTR1 relative to GAPDH, calculated using the formula 2-ΔCq,
as recommended.[43] Statistical analyses were performed using a non-parametricMann-Whit-
ney test for single comparison between FMD cases and controls and KruskalWallis test for
comparisons according to rs9349379 genotypes.
PHACTR1 Immunostaining
Protein staining for PHACTR1 was performed on paraffin embedded artery samples using
primary anti-PHACTR1 antibody (Sigma-Aldrich, St Louis, MI, USA) and revealed using an
ABC peroxidase kit with diaminobenzidine (Vector laboratories, Burlingame, CA, USA).
The paraffin blocks of arterial tissues were obtained from surgical pathology archives of the
HEGP as remnants of the regular diagnostic procedure (2 renal arteries, 1 internal carotid, 1
popliteal and 1 femoral artery). FMD arteries belonged to patients who had surgical repara-
tion for aneurysm resection (1 carotid, 1 radial, 1 coeliac, 1 ulnar and 1 pancreaticoduodenal
artery). The arterial tissues were fixed in formalin and embedded in paraffin. Antigen
retrieval were performed by incubating tissue sections in alkaline solution (Dako, Trappes,
France) for 40 minutes at 94°C in a hot water bath. The sections were then incubated for 60
minutes with the primary anti-PHACTR1 rabbit polyclonal antibody diluted at 1/50. For rev-
elation we used ABC peroxidase kit with diaminobenzidine (Vector laboratories, Burlin-
game, CA, USA).
Genetic Investigation of FMD
PLOS Genetics | DOI:10.1371/journal.pgen.1006367 October 28, 2016 13 / 17
Zebrafish experiments
Anti-phactr1morpholino was designed to target the exon7/intron7 boundary of zebrafish
phactr1 transcript. A non-targetingmorpholino of equivalent length but differing nucleotide
composition was injected at equivalent concentrations as a control. For injections, 0.8nL of
control of anti-phactr1morpholino was injected into single cell embryos of the Tubingen/AB
strain. For confirmation of morpholino efficacy, primers spanning the targeted boundarywere
used to amplify cDNA constructed from the isolated RNA of injected 72 hour post fertilization
embryos. All the morphological analyses as well as the knockout status of the fish were per-
formed blinded to the experimenter. For imaging studies, fish were reared under standard con-
ditions with addition of phenylthiourea to media in order to inhibit pigmentation. At 72hpf,
high-speed videography was performed as described[44] used to determine the diameter of
major vessels. Measurement of vessels was manually performed using ImageJ. For confocal
reconstructions of the embryonic vasculature, embryos obtained from lines expressing EGFP
driven by the flk promoter were used. Confocal images were obtained on a Nikon A1SiR confo-
cal. Two-dimensional projections of maximal intensity (head and torso) or averaged intensity
(trunk) were used to visualize the overall vascular architecture using ImageJ.
Supporting Information
S1 Fig. Principal component analysis using genotypes from FMD cases and controls of the
discovery stage.Data used is post quality control filtration for non-European ancestry origin
and relatedness
(TIFF)
S2 Fig. Association between Single-NucleotidePolymorphisms (SNPs) and Fibromuscular
Dysplasia (FMD). (A) Association between SNPs and FMD in global analysis. (B) Association
between SNPs and FMD in females only. The red line indicates the Bonferroni adjusted signifi-
cance threshold for 25,606 common variants tested set to P = 1.95 × 10−6.
(TIFF)
S3 Fig. Phenotypic evaluation of phactr1 knockdownzebrafish. (A) RT-PCR evaluation of
splice alteration observed followingmicroinjection of phactr1 morpholino (PHACTR1 KD). (B)
Brightfieldmicrographs of overt morphology at 60 hours post fertilization. (C) Two-dimensional
projections obtained from z-series confocal images in the head and trunk of control and phactr1
knockdown zebrafish embryos. Green represents the vascular endothelium as marked by EGFP.
Greyscale represents the correspondingDIC brightfield image of the fish head and trunk region.
HPV indicates the relative position of the developing hepatic portal vein
(TIFF)
S1 Table. Association of SNPs selected for follow-up in ARCADIA and PPS3 case control
analyses. SNP, Single Nucleotide polymorphism; Chr, Chromosome; EA, Effect allele; OR,
Odds-Ratio; CI, Confidence Intervalle. aFor genic SNPs, the relevant gene is listed; for inter-
genic SNPs nearest upstream and downstream genes are listed. bSNPs added despite a P value
in the discovery stage were above the threshold given their location in or near PHACTR1, the
most associated locus.
(DOCX)
S2 Table. Association of rs9349379 in PHACTR1 with carotid artery parameters in PPS3
controls. aAll (N = 2,458), Female (N = 975) and Males only (N = 1,483) participants of the
PPS3. βq.t. is the effect size estimated using quantile-transformed values and β is the effect size
estimated using untransformed values. P values indicated are for the analyses of quantile
Genetic Investigation of FMD
PLOS Genetics | DOI:10.1371/journal.pgen.1006367 October 28, 2016 14 / 17
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